Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France-Reference-Cited by-同舟云学术

Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France

Published:2021-11 Issue:6 Volume:41 Page:507-520
ISSN:0242-6498
Container-title:Annales de Pathologie
language:fr
Short-container-title:Annales de Pathologie

Author:

Franchet Camille,Djerroudi Lounes,Maran-Gonzalez Aurélie,Abramovici Olivia,Antoine Martine,Becette Véronique,Berghian Anca,Blanc-Fournier Cécile,Brabencova Eva,Charafe-Jauffret Emmanuelle,Chenard Marie-Pierre,Dauplat Marie-Mélanie,Delrée Paul,Duprez-Paumier Raphaëlle,Fleury Clémence,Ghnassia Jean-Pierre,Haudebourg Juliette,Leroux Agnès,MacGrogan Gaëtan,Mathieu Marie-Christine,Michenet Patrick,Penault-Llorca Frédérique,Poulet Bruno,Robin Yves Marie,Roger Pascal,Russ Elisabeth,Tixier Lucie,Treilleux Isabelle,Valent Alexander,Verriele Véronique,Vincent-Salomon Anne,Arnould Laurent,Lacroix-Triki Magali

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference48 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. Targeted therapies in HER2-positive breast cancer – a systematic review;Schramm;Breast Care Basel Switz,2015

3. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline focused update;Wolff;J Clin Oncol,2018

4. Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France;Penault-Llorca;Ann Pathol,2014

5. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma;Modern Pathology;2024-10

2. Recomendaciones de la sociedad argentina de patología para la determinación de HER2 en cáncer infiltrante de mama;Oncología Clínica;2024-08-23

3. Effect of HER2-low status on brain metastasis-free survival and survival after brain metastasis in patients with breast cancer;Clinical and Translational Oncology;2024-08-10

4. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7);The Breast;2024-08

5. HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity;Cancers;2024-05-25